Related posts
Battle of the Top Dividend ETFs : CanadaThis summary was created by AI, based on 2 opinions in the last 12 months.
Experts have noted some positive news for Bayer AG, with a US court ruling in favor of its Monsanto business in a lawsuit regarding Roundup weedkiller products. The stock saw a significant jump after this ruling and recent quarterly results beat expectations. However, concerns remain about high debt and limited growth prospects, leading to a lack of excitement among experts.
He sold it last February. When he bought it was down 50% on the Mansanto litigation. He dumped up, classic risk management.
It is priced at 50 cents on the dollar compared to its peers. In 2018 it bought Monsanto and the Roundup litigation halved the company. However it is being dealt with. It has three new drugs on the pharma side, one with no near term competitors when it comes off patent. It will probably spin out the herbicide business and sits at a very attractive price. Buy 18 Hold 8 Sell 1
On these big Chemicals you are always best to wait for an opportunity to get in. There isn't an urgent rush. This company is a monstrously big company.
Bayer AG is a American stock, trading under the symbol BAYRY-OTC on the US OTC (BAYRY). It is usually referred to as OTC:BAYRY or BAYRY-OTC
In the last year, 2 stock analysts published opinions about BAYRY-OTC. 1 analyst recommended to BUY the stock. 1 analyst recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Bayer AG.
Bayer AG was recommended as a Top Pick by on . Read the latest stock experts ratings for Bayer AG.
Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.
2 stock analysts on Stockchase covered Bayer AG In the last year. It is a trending stock that is worth watching.
On 2024-12-05, Bayer AG (BAYRY-OTC) stock closed at a price of $5.124.
There was some positive news on the 16th, after a US court ruled in favor of its Monsanto business in a lawsuit alleging that BAYRY's Roundup weedkiller products increase the risk of cancer. These claims were dismissed and the stock jumped over 10% that day. Recent quarterly results were positive and it beat on earnings and affirmed full-year guidance. It continues to be very cheap at 5.5x forward earnings but growth is not expected to be high while debt is also very high. We continue to not be overly excited here.
Unlock Premium - Try 5i Free